Skip to main content
. 2021 May 13;147(7):1–7. doi: 10.1001/jamaoto.2021.0835

Table 2. Number and Total Charges for All Imaging Studies.

Group No. of imaging studies Total charges (in thousands), $
Entire surveillance period
All patients (N = 136)
Mean (SD) 14.1 (10.2) 36.8 (24.5)
Median (range) 11 (0-49) 34.5 (0.0-110.9)
No recurrence (n = 109)
Mean (SD) 13.4 (9.9) 35.0 (21.7)
Median (range) 11 (0-49) 34.5 (0.0-93.5)
Recurrence (n = 27)
Mean (SD) 17.0 (11.2) 44.3 (33.1)
Median (range) 14 (3-38) 34.7 (5.3-110.9)
Mean difference (95% CI) 3.7 (−0.7 to 8.0) 9.3 (−4.3 to 23.0)
Per year of surveillance
All patients (N = 136)
Mean (SD) 4.8 (4.2) 11.8 (8.2)
Median (range) 4 (0-18) 10.0 (0.0-40.0)
No recurrence (n = 109)
Mean (SD) 3.8 (2.5) 9.7 (5.8)
Median (range) 3 (0-17) 9.3 (0.0-25.2)
Recurrence (n = 27)
Mean (SD) 8.7 (6.6) 20.3 (10.9)
Median (range) 8 (1-32) 22.3 (1.5-40.0)
Mean difference (95% CI) 5.0 (3.4-6.6) 10.6 (6.1-15.0)
Per year of surveillance in disease-free patients
No symptoms (n = 92)
Mean (SD) 3.6 (2.5) 9.6 (5.9)
Median (range) 3 (0-17) 9.4 (0.0-25.2)
Symptoms (n = 17)
Mean (SD) 4.4 (2.9) 10.4 (5.3)
Median (range) 4 (1-14) 9.3 (2.5-22.9)
Mean difference (95% CI) 0.8 (−0.5 to 2.1) 0.8 (−2.2 to 3.9)
Per year of surveillance in patients with recurrence
No symptoms (n = 14)
Mean (SD) 10.3 (7.5) 23.8 (9.3)
Median (range) 8 (2-17) 23.4 (8.3-40.0)
Symptoms (n = 13)
Mean (SD) 7.1 (5.3) 16.5 (11.6)
Median (range) 8 (1-18) 19.2 (1.5-32.8)
Mean difference (95% CI) −3.2 (−8.4 to 2.0) −7.4 (−15.7 to 0.9)